Prof Chan Cheah speaks to ecancer about the phase 3 SOUNDTRACK F1 trial evaluating surovatamig, a CD19xCD3 T cell engaging bispecific antibody, in combination with rituximab for previously untreated follicular lymphoma (FL) with high tumour burden.
The study compares two dose levels of surovatamig added to standard rituximab in a global multicenter randomized setting, with the goal of establishing safety, tolerability, and the recommended phase 3 dose.

At a median follow-up of 6.3 months, the combination demonstrated very high efficacy, with overall response rates of 95 percent and 100 percent and complete response rates of approximately 84 to 85 percent across dose levels. Deep responses were further supported by high rates of minimal residual disease negativity in evaluable patients.

The safety profile was manageable, with all patients experiencing at least one treatment emergent adverse event, most commonly infusion related reactions, fatigue, and transient cytopenias.

Cytokine release syndrome occurred in a minority of patients and was predominantly low grade, with no treatment discontinuations or grade 5 events reported.

Dr Cheah says that these findings support 7.2 mg as the recommended phase 3 dose and confirm the feasibility of combining surovatamig with rituximab in frontline follicular lymphoma treatment.